Bluestone Jeffrey 4
4 · GILEAD SCIENCES, INC. · Filed Nov 27, 2024
Insider Transaction Report
Form 4
Bluestone Jeffrey
Director
Transactions
- Sale
Common Stock
2024-11-26$91.39/sh−6,788$620,356→ 8,920 total - Exercise/Conversion
Non-qualified Stock Option (Right to Buy)
2024-11-26−5,879→ 0 totalExercise: $61.17Exp: 2030-12-08→ Common Stock (5,879 underlying) - Exercise/Conversion
Common Stock
2024-11-26$61.17/sh+5,879$359,618→ 11,587 total - Exercise/Conversion
Non-qualified Stock Option (Right to Buy)
2024-11-26−4,121→ 11,730 totalExercise: $61.35Exp: 2032-05-05→ Common Stock (4,121 underlying) - Exercise/Conversion
Common Stock
2024-11-26$61.35/sh+4,121$252,823→ 15,708 total
Footnotes (3)
- [F1]Sale prices reported for the transactions reported here range from $91.3901 to $91.3910. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- [F2]25% of the shares subject to the option vest on each three-month anniversary measured from December 8, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable on December 8, 2021.
- [F3]100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022.